About amarin corp. plc - AMRN
Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
AMRN At a Glance
Amarin Corp. Plc
Iconic Offices, The Greenway
Dublin, Dublin 2
Phone | 353-1-6699-020 | Revenue | 308.10M | |
Industry | Pharmaceuticals: Major | Net Income | -59,341,122.34 | |
Sector | Health Technology | Employees | 275 | |
Fiscal Year-end | 12 / 2024 | |||
View SEC Filings |
AMRN Valuation
P/E Current | N/A |
P/E Ratio (with extraordinary items) | N/A |
P/E Ratio (without extraordinary items) | N/A |
Price to Sales Ratio | 1.151 |
Price to Book Ratio | 0.644 |
Price to Cash Flow Ratio | 51.35 |
Enterprise Value to EBITDA | -2.915 |
Enterprise Value to Sales | 0.137 |
Total Debt to Enterprise Value | 0.207 |
AMRN Efficiency
Revenue/Employee | 1,120,365.851 |
Income Per Employee | -215,785.899 |
Receivables Turnover | 2.307 |
Total Asset Turnover | 0.359 |
AMRN Liquidity
Current Ratio | 2.796 |
Quick Ratio | 1.799 |
Cash Ratio | 1.239 |
AMRN Profitability
Gross Margin | 65.753 |
Operating Margin | -5.665 |
Pretax Margin | -17.487 |
Net Margin | -19.26 |
Return on Assets | -6.909 |
Return on Equity | -10.343 |
Return on Total Capital | -10.581 |
Return on Invested Capital | -10.177 |
AMRN Capital Structure
Total Debt to Total Equity | 1.583 |
Total Debt to Total Capital | 1.558 |
Total Debt to Total Assets | 1.051 |
Long-Term Debt to Equity | 1.583 |
Long-Term Debt to Total Capital | 1.558 |